|
|
| (8 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__ | | __NOTOC__ |
| | '''For patient information click [[{{PAGENAME}} (patient information)|here]]''' |
| {{Tropical_spastic_paraparesis}} | | {{Tropical_spastic_paraparesis}} |
| {{CMG}} | | {{CMG}} |
|
| |
|
| {{SK}} Tropical spastic paraplegia; TSP | | {{SK}} Tropical spastic paraplegia |
| ==Overview==
| |
|
| |
|
| '''Tropical spastic paraparesis''' ('''TSP''') is an [[infection]] of the [[spinal cord]] by [[Human T-lymphotropic virus]] resulting in [[paraparesis]] or weakness of the legs. As the name suggests, it is most common in [[tropical]] regions, including the [[Caribbean]] and [[Africa]].
| | ==[[Tropical spastic paraparesis overview|Overview]]== |
|
| |
|
| ==History== | | ==[[Tropical spastic paraparesis historical perspective|Historical Perspective]]== |
| For several decades the term tropical spastic paraparesis was used to describe a chronic and progressive clinical syndrome that affected adults living in equatorial areas of the world. This condition was initially thought to be associated with infectious agents (such as [[Treponema pertenue]] and [[Treponema pallidum]] which cause inflammation of the [[central nervous system]]) and with chronic nutritional deficiencies (such as [[avitaminosis]]) or exposure to potentially toxic foods (such as bitter [[cassava]]). Neurological and modern neuroepidemiological studies found that in some individuals no single cause could explain the progressive weakness, sensory disturbance, and sphincter dysfunction that affected individuals with TSP. In spite of public health programs created to eradicate the above-mentioned infectious and nutritional conditions in the tropics, large numbers of people continued to be affected.
| | ==[[Tropical spastic paraparesis classification|Classification]]== |
| | | ==[[Tropical spastic paraparesis pathophysiology|Pathophysiology]]== |
| During the mid-1980s, an important association was established between the first human retrovirus-human T-cell lymphotrophic virus type 1 (also known as [[HTLV-1]])-and idiopathic TSP (idiopathic means of unknown origin). Since then, this condition has been named HTLV-1 associated myelopathy/ tropical spastic paraparesis or HAM/TSP and scientists now understand that it is a condition caused by a [[virus]] that results in immune dysfunction.
| | ==[[Tropical spastic paraparesis causes|Causes]]== |
| | | ==[[Tropical spastic paraparesis differential diagnosis|Differentiating Tropical spastic paraparesis from other Diseases]]== |
| ==Presentation== | | ==[[Tropical spastic paraparesis epidemiology and demographics|Epidemiology and Demographics]]== |
| Patients with HAM/TSP may also exhibit [[uveitis]] (inflammation of the uveal tract of the eye), [[arthritis]] (inflammation of one or more joints), [[alveolitis|pulmonary lymphocytic alveolitis]] (inflammation of the lung tissues), [[polymyositis]] (an inflammatory muscle disease), [[keratoconjunctivitis sicca]] (persistent dryness of the cornea and conjunctiva), and [[dermatitis|infectious dermatitis]] (inflammation of the skin). Co-factors that may play a role in transmitting the disorder include being a recipient of transfusion blood products (especially before 1989), [[breast feeding|breastmilk feeding]] from a [[seropositive]] mother, [[intravenous drug]] use, or being the sexual partner of a seropositive individual for several years. Not every HTLV-1 seropositive carrier will become a HAM/TSP patient. Fewer than 5% will exhibit neurological dysfunction or, eventually, hematological malignancy such as [[adult T-cell leukemia]]/lymphoma, suggesting that other host or viral factors are responsible for disease onset.
| | ==[[Tropical spastic paraparesis risk factors|Risk Factors]]== |
| | | ==[[Tropical spastic paraparesis natural history, complications and prognosis|Natural History, Complications and Prognosis]]== |
| ==Pathogenesis== | | ==Diagnosis== |
| When infected by [[HTLV-1]] the host mounts an antigen specific immune response towards the [[HTLV-1]] antigen. [[Cytotoxic T-lymphocytes]] of the host’s immune response release [[cytokines]] in an effort to fight the infection. These [[cytokines]] facilitate the [[endothelium|transendothelial]] migration of [[lymphocytes]] across the blood-brain barrier. Once [[cytokines]] are within the central nervous system demyelination is brought as a result of bystander cell injury. The disease is [[chronic (medicine)|chronic]], progressing slowly, usually causing symptoms 20-30 years after infection.
| | [[Tropical spastic paraparesis history and symptoms|History and Symptoms]] | [[Tropical spastic paraparesis physical examination|Physical Examination]] | [[Tropical spastic paraparesis laboratory findings|Laboratory Findings]] | [[Tropical spastic paraparesis other diagnostic studies|Other Diagnostic Studies]] |
| | |
| ==Symptoms== | |
| * Progressive muscle weakness;
| |
| * Sensory disturbance
| |
| * [[Sphincter]] dysfunction
| |
| * [[Urinary]] incontinence
| |
| * [[Uveitis]]
| |
| * [[arthritis]]
| |
| * Pulmonary lymphocyte alveolitis
| |
| * [[Polymyositis]]
| |
| * [[Keratoconjunctivitis]] sicca
| |
| * Infectious [[dermatitis]]
| |
| | |
| ==Prevention==
| |
| Blood transfusion products are screened for [[HTLV-1]] antibodies.
| |
|
| |
|
| ==Treatment== | | ==Treatment== |
| There is no established treatment program for HAM/TSP although some patients may be given [[steroids]]. Clinical studies using [[interferon|interferon alpha]] and [[plasmapheresis]] have not shown significant patient improvement. [[Spasticity]] may be treated with [[lioresal]] or [[tizanidine]]. Urinary dysfunction should be treated with self-catheterization or [[oxybutynin]].
| | [[Tropical spastic paraparesis medical therapy|Medical Therapy]] | [[Tropical spastic paraparesis primary prevention|Primary Prevention]] | [[Tropical spastic paraparesis secondary prevention|Secondary Prevention]] | [[Tropical spastic paraparesis cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Tropical spastic paraparesis future or investigational therapies|Future or Investigational Therapies]] |
|
| |
|
| ==Prognosis== | | ==Case Studies== |
| HAM/TSP is usually a progressive neurological disorder but it is rarely fatal. Most patients live for several decades after the diagnosis. Their prognosis improves if they take steps to prevent urinary tract infection and skin sore formation, and if they enroll in physical and occupational therapy programs.
| | [[Tropical spastic paraparesis case study one|Case #1]] |
|
| |
|
| ==References==
| |
| * {{cite journal |author=Machigashira N, Yoshida Y, Wang S, Osame M |title=HTLV-1-associated myelopathy/tropical spastic paraparesis with pseudohypoparathyroidism |journal=Neurology |volume=56 |issue=1 |pages=104-6 |year=2001 |pmid=11148245 |url=http://www.neurology.org/cgi/content/full/56/1/104}}
| |
|
| |
|
| {{Diseases of the nervous system}} | | {{Diseases of the nervous system}} |
| Line 47: |
Line 30: |
|
| |
|
| [[Category:Viral diseases]] | | [[Category:Viral diseases]] |
| [[Category:Infectious disease]]
| | |
| [[Category:Neurology]] | | [[Category:Neurology]] |
|
| |
|